<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732107</url>
  </required_header>
  <id_info>
    <org_study_id>GU12-157</org_study_id>
    <nct_id>NCT01732107</nct_id>
  </id_info>
  <brief_title>Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression</brief_title>
  <official_title>A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noah Hahn, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the 6-month complete response rate and toxicity profile of oral
      dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3
      mutations or over-expression who are ineligible for or refusing cystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
           Day 12 assessments are intended to be performed on the last dosing day of the 2nd week
           in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last
           dosing day of the 4th week in cycle 1 and cycle 2.

        -  Standard of Care: Cystoscopy with tumor biopsy, bladder biopsy, urine cytology

        -  Physician discretion: Anti-emetic medications and/or colony stimulating growth factors

      ECOG performance status 0 - 2

      Hematopoietic:

        -  White blood cell count (WBC) &gt; 3.0 K/mm3

        -  Absolute neutrophil count (ANC) ≥ 1.5 K/mm3

        -  Platelets ≥ 100 K/mm3

        -  Hemoglobin (Hgb) ≥ 9 g/dL

      Hepatic:

        -  Serum total bilirubin: ≤ 1.5 x Upper limit of normal (ULN)

        -  Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3.0 x ULN

      Renal:

        -  Serum creatinine ≤ 1.5 x ULN or serum creatinine &gt; 1.5 - 3 x ULN if calculated
           creatinine clearance (CrCl) is ≥ 30 mL/min using the Cockcroft-Gault equation

      Cardiovascular:

      No impaired cardiac function or clinically significant cardiac diseases, including any of the
      following:

        -  History or presence of serious uncontrolled ventricular arrhythmias

        -  Clinically significant resting bradycardia

        -  LVEF assessed by 2-D echocardiogram (ECHO) &lt; 50% or lower limit of normal (whichever is
           higher) or multiple gated acquisition scan (MUGA), &lt; 45% or lower limit of normal
           (whichever is higher)

        -  Myocardial Infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG),
           Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic
           Attack (TIA), Pulmonary Embolism (PE)within 6 months prior to starting study drug
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding withdrawn due to slow accrual
  </why_stopped>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">March 6, 2017</completion_date>
  <primary_completion_date type="Actual">March 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine 6-Month Complete Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>The 6-month complete response rate is defined as the proportion of patients treated with dovitinib with no evidence of any remaining urothelial carcinoma tumors of any T-stage (including Tis) present within the bladder as assessed by standard of care cystoscopic examination with transurethral resection of bladder tumor (TURBT) and urine cytology performed at 6 months after initiation of study therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine 1-Year Relapse-Free Survival Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The 1-year relapse free survival rate is defined as the proportion of patients treated with dovitinib with no evidence of any remaining urothelial carcinoma tumors at 12 months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Rate of Progression to Muscle-Invasive Stage</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of progression to muscle-invasive stage for dovitinib is defined as the proportion of patients with clinical or pathologic progression to muscle-invasive stages (i.e., T2-T4) at any time point on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine 3-Month and 6-Month Partial Response Rates</measure>
    <time_frame>6 months</time_frame>
    <description>The 3- and 6-month partial response rates are defined as the proportion of patients treated with persistent but reduced T-stage tumors on post-therapy TURBT (i.e., T1 ≥ Ta; T1+Tis ≥ T1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Treatment-related Toxicity Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment-related toxicity rates will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Characterize pre- and post-treatment bladder tumor FGFR pathway phosphorylation changes.</measure>
    <time_frame>12 months</time_frame>
    <description>Pre- and post-treatment bladder tumor FGFR pathway phosphorylation changes will be assessed by bladder tumor tissue immunohistochemistry utilizing commercially available antibodies including, but not limited to, the following: fibroblast growth factor receptors (FGFR3, pFGFR3), vascular endothelial growth factor receptors (VEGFR2, pVEGFR2), fibroblast growth factor receptor substrates (2FRS2, pFRS2), extracellular signal-regulated kinases (ERK), phosphorylated extracellular signal-related kinase (pERK).</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize associations between pre-treatment germline, FGFR single-nucleotide polymorphisms (SNPs) and post-treatment 6-month complete response rate and 1-year relapse free survival rate in patients treated with dovitinib.</measure>
    <time_frame>12 months</time_frame>
    <description>Pre-treatment germline FGFR SNPs will be assessed by testing extracted Deoxyribonucleic acid (DNA) from patient peripheral blood mononuclear cells (PBMC's) (collected prior to initiating dovitinib therapy) with validated commercial probes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize pre- and post-treatment VEGFR pathway phosphorylation changes as assessed by bladder tumor tissue immunohistochemistry.</measure>
    <time_frame>12 months</time_frame>
    <description>Pre- and post-treatment bladder tumor VEGFR pathway phosphorylation changes will be assessed by bladder tumor tissue immunohistochemistry utilizing commercially available antibodies including, but not limited to, the following: FGFR3, pFGFR3, VEGFR2, pVEGFR2, FRS2, pFRS2, ERK, pERK.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize associations between pre-treatment germline VEGFR SNPs and post-treatment 6-month complete response rate and 1-year relapse free survival rate in patients treated with dovitinib.</measure>
    <time_frame>12 months</time_frame>
    <description>Pre-treatment germline VEGFR SNPs will be assessed by testing extracted DNA from patient PBMC's (collected prior to initiating dovitinib therapy) with validated commercial probes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize associations between post-treatment hypertension, 6-month complete response rate and 1-year relapse free survival rate in patients treated with dovitinib.</measure>
    <time_frame>12 months</time_frame>
    <description>Hypertension will be defined as a systolic blood pressure (SBP) of &gt; 140 mmHg or a diastolic blood pressure (DBP) of &gt; 90 mm Hg recorded at any time after dovitinib therapy is initiated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize concordance rates between UC patient detected tumor, urine, and circulating free plasma FGFR3 mutations.</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of FGFR3 mutations within patient free plasma will be assessed by polymerase chain reaction (PCR) amplification of the target regions and sequencing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize post-treatment bladder tissue dovitinib concentrations.</measure>
    <time_frame>12 months</time_frame>
    <description>Post-treatment bladder tissue dovitinib concentrations will be assessed by TURBT fresh frozen tissue obtained at the 3-month cystoscopy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Dovitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovitinib</intervention_name>
    <description>Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.</description>
    <arm_group_label>Dovitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed early stage urothelial carcinoma of the bladder defined as
             Ta, T1, or Tis stage.

          -  Presence of either an FGFR3 mutation or FGFR3 over-expression within bladder tumor
             tissue.

          -  Documented BCG-refractory disease defined as failure to achieve a tumor free state
             after at least 2 prior induction courses of intravesical BCG therapy.

          -  Medically unfit to undergo cystectomy or electively choosing to forego cystectomy

          -  Patients who give a written informed consent obtained according to local guidelines

        Exclusion Criteria:

          -  Patients with muscle-invasive (i.e. T2, T3, T4), locally advanced non-resectable, or
             metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained
             within 28 days prior to study registration.

          -  Patients with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive
             urothelial carcinoma.

          -  Patients with another primary malignancy within 3 years prior to starting study drug,
             with the exception of adequately treated in-situ carcinoma of the uterine cervix,
             clinically localized prostate cancer, biochemically relapsed non-metastatic prostate
             cancer (i.e., PSA only disease), or skin cancer (such as basal cell carcinoma,
             squamous cell carcinoma, or non-melanomatous skin cancer)

          -  Patients who have received the last administration of an anti-cancer therapy including
             chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting
             study drug, or who have not recovered from the side effects of such therapy

          -  Patients who have received prior VEGFR-targeted or FGFR-targeted agents (i.e.,
             sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, etc.).

          -  Patients who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have
             not recovered from radiotherapy toxicities

          -  Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
             intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting
             study drug, or patients who have had minor procedures (i.e., TURBT), percutaneous
             biopsies or placement of vascular access device ≤ 1 week prior to starting study drug,
             or who have not recovered from side effects of such procedure or injury

          -  Uncontrolled hypertension defined by a systolic blood pressure (SBP) ≥ 160 mm Hg
             and/or d iastolic blood pressure (DBP) ≥ 100 mm Hg, with or without anti-hypertensive
             medication(s)

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of dovitinib (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  Cirrhosis, chronic active hepatitis or chronic persistent hepatitis

          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
             mandatory)

          -  Patients who are currently receiving anti-coagulation treatment with therapeutic doses
             of warfarin. Full-dose anti-coagulation with low molecular weight heparin is
             permitted.

          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,
             active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable
             safety risks or compromise compliance with the protocol

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential, who are biologically able to conceive, not employing
             two forms of highly effective contraception. Highly effective contraception must be
             used throughout the trial and up to 8 weeks after the last dose of study drug (e.g.
             male condom with spermicidal; diaphragm with spermicide; intra-uterine device). Oral,
             implantable, or injectable contraceptives that may be affected by cytochrome P450
             interactions are not considered effective for this study. Women of child-bearing
             potential, defined as sexually mature women who have not undergone a hysterectomy or
             who have not been naturally postmenopausal for at least 12 consecutive months (i.e.,
             who has had menses any time in the preceding 12 consecutive months), must have a
             negative serum pregnancy test ≤ 14 days prior to starting study drug.

          -  Fertile males not willing to use contraception, as stated above

          -  Patients unwilling or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noah Hahn, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center Extramural Research Program</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2012</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Noah Hahn, M.D.</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Dovitinib</keyword>
  <keyword>FGFR3 Mutations</keyword>
  <keyword>BCG-Refractory Urothelial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

